Maintenance Strategy and Technological Evolution of Equipment in Peptide Purification Manufacturing Facilities

Peptide purification is the core downstream segment of therapeutic peptide production, which directly determines product purity, impurity profile, endotoxin control and batch-to-batch consistency. Production-grade purification plants mainly rely on preparative chromatography systems, dynamic axial compression (DAC) columns, membrane filtration modules, buffer preparation skids, fraction collection and lyophilisation units. The stable performance of these assets depends on standardised preventive maintenance, corrective troubleshooting and GMP-compliant cleaning validation. This paper systematically discusses classification of maintenance activities, common failure modes of key purification equipment, and explores the technical evolution direction of peptide purification hardware, including continuous chromatography, digitalised predictive maintenance, green solvent-compatible hardware and modular biomanufacturing platforms, without commercial promotion of specific brands or products.

1. Introduction

Therapeutic peptides have strict regulatory requirements on residual solvents, truncated peptide impurities and microbial contamination. Unlike general fine chemical separation, peptide purification equipment operates under repeated cycles of acidic, basic and organic mobile phases. Proteinaceous peptide deposits, salt precipitation and stationary phase degradation gradually damage flow paths, seals, sensors and chromatography media. Poor maintenance may lead to rising backpressure, peak tailing, retention time drift, cross-contamination and batch rejection. Therefore, a lifecycle-based equipment maintenance system is essential for peptide purification plants. Meanwhile, the industry is shifting from discontinuous batch preparative HPLC toward continuous, low-solvent, digitally controlled purification hardware to address high process mass intensity (PMI) and scaling bottlenecks of traditional batch chromatography.

2. Classification and Implementation of Equipment Maintenance in Peptide Purification Plants

Maintenance activities are divided into preventive maintenance, predictive maintenance, corrective maintenance and shutdown overhaul, all documented within GMP equipment logbooks, SOPs and cleaning validation records.

2.1 Preventive Maintenance (Planned Routine Maintenance)

Preventive maintenance is scheduled according to operating hours, batch counts and manufacturer specifications, aiming to reduce unplanned downtime and avoid product cross-contamination.

1. Preparative chromatography systems (pumps, UV/conductivity/pH detectors, fraction collectors) Daily routine: visual inspection for leakage at PEEK fittings, tubing cracks and blockage; system flushing after batch run to remove adsorbed peptide and salt residues; verification of baseline stability of UV detectors. Buffer and feed lines must be purged to prevent salt crystallisation inside pump heads and check valves. Weekly maintenance: calibration of flow rate, pressure transducers, conductivity and pH probes; inspection and replacement of inline guard filters. Rising system backpressure is monitored as a key early warning indicator. Quarterly maintenance: disassembly and ultrasonic cleaning of check valves; replacement of piston seals and wash seals; leak test of the entire fluidic circuit. PEEK tubing and ferrules are inspected for microcracks induced by repeated pressure cycling. Annual recertification: full system performance qualification, including resolution test with peptide reference standard, delay volume verification and electronic audit trail validation for GMP compliance.

2. DAC preparative chromatography columns DAC columns are the core separation hardware for large-scale peptide purification. Preventive maintenance focuses on bed integrity and media protection. After each purification cycle, cleaning-in-place (CIP) is performed using validated alkaline or acidic solutions to strip adsorbed peptides and endotoxin. Column bed height and packing uniformity are checked periodically to detect channeling or bed settlement. Guard cartridges are replaced on a defined schedule. Storage procedures require columns to be preserved in suitable aqueous-organic preservative solution to inhibit microbial growth and prevent stationary phase degradation. Column usage cycles are recorded; once resolution declines or irreversible backpressure increase occurs, media repacking or replacement is executed.

3. Membrane filtration and nanofiltration units Tangential flow filtration (TFF) and nanofiltration modules are used for peptide concentration, buffer exchange and endotoxin reduction. Daily checks include transmembrane pressure (TMP) and permeate flux. Preventive maintenance includes post-run CIP, integrity test of filter membranes before each batch, periodic replacement of membrane cassettes and pre-filters. Salt and peptide fouling must be eliminated to avoid irreversible membrane adsorption.

4. Buffer preparation skids and lyophilisation equipment Buffer preparation tanks, mixing agitators, conductivity sensors and sterile filters require periodic sanitisation and calibration. For lyophilizers used for final peptide isolation, maintenance covers vacuum system leak detection, refrigeration compressor inspection, temperature probe calibration and chamber sterilisation verification.

2.2 Predictive Maintenance

Modern peptide plants gradually deploy predictive maintenance based on real-time process data. Sensors continuously capture backpressure, pump vibration, UV baseline noise, conductivity drift and flow fluctuation. Data trends are analysed to predict seal ageing, column fouling or valve wear before functional failure. This shifts maintenance from fixed time intervals to condition-based intervention, reducing unnecessary component replacement and minimising production interruption.

2.3 Corrective Maintenance and Deviation Management

When abnormal phenomena appear such as sudden pressure spikes, leakage, peak distortion or detector signal drift, corrective maintenance shall be triggered. All breakdown events, root cause analysis, repair work, re-calibration and requalification must be fully recorded in deviation reports. After repair, equipment cannot be released for production until performance verification passes. For shared multi-product purification lines, extra cleaning verification shall be implemented after corrective maintenance to rule out cross-contamination risks.

3. Common Equipment Degradation Risks and Maintenance Control Points

Peptide mobile phases contain trifluoroacetic acid, acetonitrile, sodium hydroxide and phosphate salts, which accelerate material fatigue.

1. Fluidic path corrosion and seal failure: Piston seals, O-rings and valve diaphragms are vulnerable to erosion by organic solvents and extreme pH, leading to internal leakage and flow inaccuracy. Seal washing systems must operate continuously during runs.

2. Media fouling and bed channeling: Hydrophobic peptide aggregates and precipitated salts adhere to stationary phase surfaces, reducing resolution. Incomplete CIP will cause cumulative fouling and endotoxin accumulation.

3. Sensor drift: UV lamps degrade over time; pH and conductivity probes are contaminated by peptide deposits, leading to incorrect parameter feedback and elution condition deviation.

4. **Microbial contamination in stagnant sections: dead legs in pipelines, unused fraction loops and stored columns are prone to biofilm formation if improperly preserved.

Critical control principle: maintenance and cleaning activities shall be linked with cleaning validation, and residue acceptance criteria shall cover target peptide, related impurities and endotoxin.

4. Future Technological Development of Peptide Purification Equipment

The development trend of purification hardware is driven by demands of higher productivity, lower solvent consumption, improved sustainability and robust digital process control.

4.1 Continuous Multi-Column Chromatography Hardware Replacing Traditional Batch Preparative HPLC

Conventional single-column batch chromatography has low utilisation of stationary phase and high solvent consumption. Multi-column counter-current solvent gradient purification (MCSGP) and simulated moving bed (SMB) systems enable continuous capture and reprocessing of side fractions online without intermediate isolation. This improves peptide recovery and cuts organic solvent consumption substantially. New generation continuous purification skids are designed with integrated automatic fraction diversion, real-time UV trigger switching and pressure interlock protection. Hardware material compatibility is optimised for repeated recycling of mobile phases. Continuous purification equipment will become mainstream for commercial-scale production of medium and long-chain therapeutic peptides, especially for high-volume peptide APIs.

4.2 Digital and AI-enabled Integrated Purification Platforms

Future plants will integrate distributed control systems (DCS) with equipment asset management modules. Real-time operational data from pumps, columns and sensors are aggregated into a central platform. Machine learning models can predict column fouling rate, recommend optimal CIP duration and judge whether chromatography media requires repacking. AI algorithms may also assist in adjusting elution gradient parameters according to impurity profiles, reducing manual intervention. Digital twin technology can simulate pressure distribution inside DAC columns and pipeline dead legs during process development, supporting equipment design optimisation and risk assessment before physical commissioning.

4.3 Green Manufacturing-oriented Hardware Upgrades

Traditional peptide purification consumes large volumes of acetonitrile and TFA. New equipment is being engineered to adapt to greener mobile phase modifiers including ethanol and biodegradable organic solvents. Modular solvent recovery units are integrated directly onto purification skids to recycle eluents on-site, lowering PMI and waste treatment load. In parallel, new column hardware is developed for low-shearing packing of novel biocompatible stationary phases. Material selection of wetted components will be further optimised to resist milder acidic modifiers and reduce fluorinated reagent reliance.

4.4 Modular, Flexible and Compact Purification Skids

Traditional fixed dedicated purification lines lack flexibility for multi-product peptide workshops. Next-generation equipment adopts modular skid design: chromatography unit, TFF concentration, buffer preparation and fraction collection can be rapidly reconfigured, cleaned and validated for different peptide products. Modular hardware reduces capital investment and shortens product switchover time, suitable for CDMO facilities producing multiple peptide candidates at different batch scales. Single-use flow paths are also under research for small-batch clinical-grade peptide purification, lowering cleaning validation burden and cross-contamination risk.

4.5 Advanced Separation Hardware Coupled with Online Analytical Monitoring

Future purification systems will embed inline mass spectrometry or multi-wavelength UV detectors, enabling real-time identification of target peptide and impurities. Closed-loop automatic adjustment of elution gradient, flow rate and fraction cut points can be realised without offline sampling. Combined with advanced nanofiltration and affinity capture hardware, integrated separation trains will simplify multi-step peptide purification workflows.

5. Conclusion

Reliable peptide purification production depends on rigorous, GMP-aligned equipment maintenance covering routine inspection, preventive replacement, cleaning validation and condition-based predictive monitoring. Key failure modes such as seal degradation, column bed damage, sensor drift and fouling must be managed through structured maintenance SOPs and complete documentation. In the long run, peptide purification equipment will evolve toward continuous multi-column separation, digital predictive asset management, green solvent compatible wetted materials and modular flexible biomanufacturing. The hardware innovation aims to solve the high cost, high solvent consumption and batch variability limitations of conventional batch chromatography, supporting scalable, sustainable and high-quality production of therapeutic peptides.